The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
BIL also holds an option to increase its equity stake by an additional 15%
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
The emergence of new infections in India is a growing concern
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
Subscribe To Our Newsletter & Stay Updated
